Payment overview · 2025
General Payments
$4,137.68
197 reported records · 28 companies
Healthcare provider profile · identity verified
Daisy Li
Allopathic & Osteopathic Physicians|Family Medicine · STOCKTON, CA · NPI 1740770007
Verified facts
What the public records show
CMS Open Payments records show Daisy Li received $4,137.68 in general payments during 2025 across 197 reported records.
Lilly USA, LLC accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $562.21 | 13.6% | 25 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $392.63 | 9.5% | 16 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $319.42 | 7.7% | 18 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $267.70 | 6.5% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $246.37 | 6.0% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $227.04 | 5.5% | 13 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $226.61 | 5.5% | 9 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $226.32 | 5.5% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $200.12 | 4.8% | 12 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $199.22 | 4.8% | 11 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $189.33 | 4.6% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $178.64 | 4.3% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $162.17 | 3.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.69 | 3.4% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $86.69 | 2.1% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $80.94 | 2.0% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $57.47 | 1.4% | 2 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $56.69 | 1.4% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $53.78 | 1.3% | 3 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $50.38 | 1.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.65 | 1.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.59 | 0.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.33 | 0.7% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $27.36 | 0.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.35 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.91 | 0.5% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $19.82 | 0.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.25 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,074.33 | 193 |
| Education | $63.35 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $498.13 | 20 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $319.42 | 18 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $246.37 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $228.11 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $227.04 | 13 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $226.32 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $217.86 | 6 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $199.22 | 11 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $189.33 | 10 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $178.64 | 7 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $161.27 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $157.84 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $140.69 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $132.83 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $126.20 | 10 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $97.81 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $80.94 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $68.44 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $64.22 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $61.06 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $57.47 | 2 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $56.69 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $53.78 | 3 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $50.38 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.65 | 3 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $30.37 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $29.33 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $3.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $3.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 97 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 85 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 128 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
85 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 34 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 34 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1135 | 283 |
| Amlodipine Besylate | Amlodipine Besylate | 732 | 181 |
| Metformin Hcl | Metformin Hcl | 423 | 111 |
| Losartan Potassium | Losartan Potassium | 367 | 90 |
| Lisinopril | Lisinopril | 338 | 106 |
| Furosemide | Furosemide | 220 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 179 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 178 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 176 | 80 |
| Gabapentin | Gabapentin | 176 | 61 |
| Simvastatin | Simvastatin | 172 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 44 |
| Famotidine | Famotidine | 164 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 161 | 85 |
| Quetiapine Fumarate | Quetiapine Fumarate | 147 | 13 |
| Divalproex Sodium | Divalproex Sodium | 143 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 67 |
| Jardiance | Empagliflozin | 128 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 119 | 67 |
| Carvedilol | Carvedilol | 118 | 18 |
| Donepezil Hcl | Donepezil Hcl | 117 | 18 |
| Atenolol | Atenolol | 111 | 32 |
| Benazepril Hcl | Benazepril Hcl | 109 | 30 |
| Eliquis | Apixaban | 97 | 20 |
| Finasteride | Finasteride | 97 | 19 |
| Allopurinol | Allopurinol | 89 | 32 |
| Omeprazole | Omeprazole | 88 | 27 |
| Farxiga | Dapagliflozin Propanediol | 85 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 28 |
| Xarelto | Rivaroxaban | 82 | 14 |
| Alendronate Sodium | Alendronate Sodium | 80 | 27 |
| Ozempic | Semaglutide | 79 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 20 |
| Sertraline Hcl | Sertraline Hcl | 68 | suppressed |
| Olanzapine | Olanzapine | 66 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 66 | suppressed |
| Risperidone | Risperidone | 64 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 60 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 60 | suppressed |
| Glipizide Er | Glipizide | 59 | 20 |
| Midodrine Hcl | Midodrine Hcl | 58 | suppressed |
| Ibuprofen | Ibuprofen | 55 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 17 |
| Mirtazapine | Mirtazapine | 53 | 15 |
| Glimepiride | Glimepiride | 50 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 13 |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Glipizide | Glipizide | 46 | 11 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 44 | suppressed |
| Hydrocortisone | Hydrocortisone | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Lidocaine | Lidocaine | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | 11 |
| Baclofen | Baclofen | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 13 |
| Alprazolam | Alprazolam | 31 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Valproic Acid | Valproic Acid | 30 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 27 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Sulfasalazine | Sulfasalazine | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 17 |
| Cephalexin | Cephalexin | 18 | 17 |
| Permethrin | Permethrin | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Methazolamide | Methazolamide | 13 | suppressed |
| Procrit | Epoetin Alfa | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,137.68 · 197 records | Lilly USA, LLC | ACTHAR, AIRSUPRA, BREZTRI, Cologuard Collection Kit, ELIQUIS, FARXIGA, Fabhalta, IBSRELA, INGREZZA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, Korlym, LUPKYNIS, MAVYRET, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, RAYALDEE, REPATHA, REXULTI, Rybelsus, SHINGRIX, TARPEYO, TAVNEOS, VELPHORO, VOYXACT, Vafseo, Veltassa, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error